Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights
Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. So far, diagnosis and prognosis of gliomas were based on histological and genetic criteria which need being completed by a panel of molecular markers. Highly distributed in brain, gap junction prot...
Gespeichert in:
| Veröffentlicht in: | Cancer medicine (Malden, MA) MA), 2016-08, Vol.5 (8), p.1742-1752 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1752 |
|---|---|
| container_issue | 8 |
| container_start_page | 1742 |
| container_title | Cancer medicine (Malden, MA) |
| container_volume | 5 |
| creator | Crespin, Sophie Fromont, Gaëlle Wager, Michel Levillain, Pierre Cronier, Laurent Monvoisin, Arnaud Defamie, Norah Mesnil, Marc |
| description | Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. So far, diagnosis and prognosis of gliomas were based on histological and genetic criteria which need being completed by a panel of molecular markers. Highly distributed in brain, gap junction proteins, connexins, could be considered as markers of glioma progression as previous studies indicated that expression of a connexin type, connexin43 (Cx43), is inversely correlated to tumor grading. However, this assumption was weakened by the low number of glioma samples used. Taking advantage of tissue microarray technique, we pursued this analysis by studying in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). Our analysis confirmed the global diminution of Cx43 expression in glioblastomas that was observed in previous studies. However, this analysis brought new insights such as the following ones. First, the high number of samples permitted to show that more than 60% of glioblastomas still express Cx43. Second, no gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, a Cx43 nuclear staining was detected in areas where leukocytes are present. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.
Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. Highly distributed in brain, gap junction proteins, such as connexin 43, could be considered as markers of glioma progression. Taking advantage of tissue microarray technique, we analyzed in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). The high number of samples shows that 60% of glioblastomas still express Cx43. No gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, the detection of a Cx43 nuclear staining seemed to be related to lymphocyte infiltrations. In conclusion, our study emphasizes the importan |
| doi_str_mv | 10.1002/cam4.730 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4971902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1809047773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4720-947ce530ba18d6ac88df04da4fb4e5a77f31c88253eeac6322e22edc79cbc8143</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhoMotrQFf4EEvFHo1HztZMYLYVmqLax4o9fhbPbMbJaZZExm-vHvzbC11oIhkHDOc96TnJeQN5xdcMbERwu9utCSvSDHgqlFoUupXj65H5GzlPYsL81EqflrciQyXpa1PCZweTdETMkFT0NDgbYw0P3k7ThHhhhGdP6c2uA93jmv5Dl1PmMdxBbpAB67uW439eBp27nQQ_pEPd5mLLl2N6ZT8qqBLuHZw3lCfn65_LG6Ktbfv16vluvCKi1YUSttcSHZBni1LcFW1bZhaguq2ShcgNaN5DkoFhIRbCmFwLy3Vtd2Yyuu5An5fNAdpk2fE-jHCJ0Zoush3psAzvyb8W5n2nBjVK15zUQW-HAQ2D0ru1quzRxjQklWc3nDM_v-oVkMvyZMo-ldsth1eSBhSoZXrGZKay0z-u4Zug9T9HkURoi5r6iV-CtoY0gpYvP4As7MbLOZbTbZt4y-ffrRR_CPqRkoDsCt6_D-v0JmtfymZsHfks2v7w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290232942</pqid></control><display><type>article</type><title>Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights</title><source>PubMed (Medline)</source><source>Wiley-Blackwell Open Access Collection</source><source>MEDLINE</source><source>Wiley Online Library Journals</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Crespin, Sophie ; Fromont, Gaëlle ; Wager, Michel ; Levillain, Pierre ; Cronier, Laurent ; Monvoisin, Arnaud ; Defamie, Norah ; Mesnil, Marc</creator><creatorcontrib>Crespin, Sophie ; Fromont, Gaëlle ; Wager, Michel ; Levillain, Pierre ; Cronier, Laurent ; Monvoisin, Arnaud ; Defamie, Norah ; Mesnil, Marc</creatorcontrib><description>Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. So far, diagnosis and prognosis of gliomas were based on histological and genetic criteria which need being completed by a panel of molecular markers. Highly distributed in brain, gap junction proteins, connexins, could be considered as markers of glioma progression as previous studies indicated that expression of a connexin type, connexin43 (Cx43), is inversely correlated to tumor grading. However, this assumption was weakened by the low number of glioma samples used. Taking advantage of tissue microarray technique, we pursued this analysis by studying in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). Our analysis confirmed the global diminution of Cx43 expression in glioblastomas that was observed in previous studies. However, this analysis brought new insights such as the following ones. First, the high number of samples permitted to show that more than 60% of glioblastomas still express Cx43. Second, no gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, a Cx43 nuclear staining was detected in areas where leukocytes are present. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.
Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. Highly distributed in brain, gap junction proteins, such as connexin 43, could be considered as markers of glioma progression. Taking advantage of tissue microarray technique, we analyzed in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). The high number of samples shows that 60% of glioblastomas still express Cx43. No gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, the detection of a Cx43 nuclear staining seemed to be related to lymphocyte infiltrations. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.730</identifier><identifier>PMID: 27306693</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Biomarkers, Tumor ; Biomarkers, Tumor - metabolism ; Blotting, Western ; Blotting, Western - methods ; Brain cancer ; Brain Neoplasms ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain tumors ; Cell Nucleus ; Cell Nucleus - metabolism ; Chemotaxis, Leukocyte ; Clinical Cancer Research ; Connexin 43 ; Connexin 43 - metabolism ; Connexins ; Cx43 ; Diagnosis ; Female ; gap junctions ; Glioblastoma ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioma ; Glioma - metabolism ; Glioma - pathology ; gliomas ; Humans ; Leukocytes ; Life Sciences ; Localization ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Proteins ; Neoplasm Proteins - metabolism ; Original Research ; Proteins ; Studies ; Tissue Array Analysis ; Tissue Array Analysis - methods ; Tumors ; Young Adult</subject><ispartof>Cancer medicine (Malden, MA), 2016-08, Vol.5 (8), p.1742-1752</ispartof><rights>2016 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4720-947ce530ba18d6ac88df04da4fb4e5a77f31c88253eeac6322e22edc79cbc8143</citedby><cites>FETCH-LOGICAL-c4720-947ce530ba18d6ac88df04da4fb4e5a77f31c88253eeac6322e22edc79cbc8143</cites><orcidid>0000-0002-7504-7538 ; 0000-0002-5088-9325 ; 0000-0003-4922-0365 ; 0000-0002-9915-4872 ; 0000-0002-7730-2264</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971902/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971902/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1416,11561,27923,27924,45573,45574,46051,46475,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27306693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02430913$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Crespin, Sophie</creatorcontrib><creatorcontrib>Fromont, Gaëlle</creatorcontrib><creatorcontrib>Wager, Michel</creatorcontrib><creatorcontrib>Levillain, Pierre</creatorcontrib><creatorcontrib>Cronier, Laurent</creatorcontrib><creatorcontrib>Monvoisin, Arnaud</creatorcontrib><creatorcontrib>Defamie, Norah</creatorcontrib><creatorcontrib>Mesnil, Marc</creatorcontrib><title>Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. So far, diagnosis and prognosis of gliomas were based on histological and genetic criteria which need being completed by a panel of molecular markers. Highly distributed in brain, gap junction proteins, connexins, could be considered as markers of glioma progression as previous studies indicated that expression of a connexin type, connexin43 (Cx43), is inversely correlated to tumor grading. However, this assumption was weakened by the low number of glioma samples used. Taking advantage of tissue microarray technique, we pursued this analysis by studying in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). Our analysis confirmed the global diminution of Cx43 expression in glioblastomas that was observed in previous studies. However, this analysis brought new insights such as the following ones. First, the high number of samples permitted to show that more than 60% of glioblastomas still express Cx43. Second, no gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, a Cx43 nuclear staining was detected in areas where leukocytes are present. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.
Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. Highly distributed in brain, gap junction proteins, such as connexin 43, could be considered as markers of glioma progression. Taking advantage of tissue microarray technique, we analyzed in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). The high number of samples shows that 60% of glioblastomas still express Cx43. No gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, the detection of a Cx43 nuclear staining seemed to be related to lymphocyte infiltrations. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Blotting, Western</subject><subject>Blotting, Western - methods</subject><subject>Brain cancer</subject><subject>Brain Neoplasms</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain tumors</subject><subject>Cell Nucleus</subject><subject>Cell Nucleus - metabolism</subject><subject>Chemotaxis, Leukocyte</subject><subject>Clinical Cancer Research</subject><subject>Connexin 43</subject><subject>Connexin 43 - metabolism</subject><subject>Connexins</subject><subject>Cx43</subject><subject>Diagnosis</subject><subject>Female</subject><subject>gap junctions</subject><subject>Glioblastoma</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Glioma</subject><subject>Glioma - metabolism</subject><subject>Glioma - pathology</subject><subject>gliomas</subject><subject>Humans</subject><subject>Leukocytes</subject><subject>Life Sciences</subject><subject>Localization</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Proteins</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Original Research</subject><subject>Proteins</subject><subject>Studies</subject><subject>Tissue Array Analysis</subject><subject>Tissue Array Analysis - methods</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kV1rFDEUhoMotrQFf4EEvFHo1HztZMYLYVmqLax4o9fhbPbMbJaZZExm-vHvzbC11oIhkHDOc96TnJeQN5xdcMbERwu9utCSvSDHgqlFoUupXj65H5GzlPYsL81EqflrciQyXpa1PCZweTdETMkFT0NDgbYw0P3k7ThHhhhGdP6c2uA93jmv5Dl1PmMdxBbpAB67uW439eBp27nQQ_pEPd5mLLl2N6ZT8qqBLuHZw3lCfn65_LG6Ktbfv16vluvCKi1YUSttcSHZBni1LcFW1bZhaguq2ShcgNaN5DkoFhIRbCmFwLy3Vtd2Yyuu5An5fNAdpk2fE-jHCJ0Zoush3psAzvyb8W5n2nBjVK15zUQW-HAQ2D0ru1quzRxjQklWc3nDM_v-oVkMvyZMo-ldsth1eSBhSoZXrGZKay0z-u4Zug9T9HkURoi5r6iV-CtoY0gpYvP4As7MbLOZbTbZt4y-ffrRR_CPqRkoDsCt6_D-v0JmtfymZsHfks2v7w</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Crespin, Sophie</creator><creator>Fromont, Gaëlle</creator><creator>Wager, Michel</creator><creator>Levillain, Pierre</creator><creator>Cronier, Laurent</creator><creator>Monvoisin, Arnaud</creator><creator>Defamie, Norah</creator><creator>Mesnil, Marc</creator><general>John Wiley & Sons, Inc</general><general>Wiley</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7504-7538</orcidid><orcidid>https://orcid.org/0000-0002-5088-9325</orcidid><orcidid>https://orcid.org/0000-0003-4922-0365</orcidid><orcidid>https://orcid.org/0000-0002-9915-4872</orcidid><orcidid>https://orcid.org/0000-0002-7730-2264</orcidid></search><sort><creationdate>201608</creationdate><title>Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights</title><author>Crespin, Sophie ; Fromont, Gaëlle ; Wager, Michel ; Levillain, Pierre ; Cronier, Laurent ; Monvoisin, Arnaud ; Defamie, Norah ; Mesnil, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4720-947ce530ba18d6ac88df04da4fb4e5a77f31c88253eeac6322e22edc79cbc8143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Blotting, Western</topic><topic>Blotting, Western - methods</topic><topic>Brain cancer</topic><topic>Brain Neoplasms</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain tumors</topic><topic>Cell Nucleus</topic><topic>Cell Nucleus - metabolism</topic><topic>Chemotaxis, Leukocyte</topic><topic>Clinical Cancer Research</topic><topic>Connexin 43</topic><topic>Connexin 43 - metabolism</topic><topic>Connexins</topic><topic>Cx43</topic><topic>Diagnosis</topic><topic>Female</topic><topic>gap junctions</topic><topic>Glioblastoma</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Glioma</topic><topic>Glioma - metabolism</topic><topic>Glioma - pathology</topic><topic>gliomas</topic><topic>Humans</topic><topic>Leukocytes</topic><topic>Life Sciences</topic><topic>Localization</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Proteins</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Original Research</topic><topic>Proteins</topic><topic>Studies</topic><topic>Tissue Array Analysis</topic><topic>Tissue Array Analysis - methods</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crespin, Sophie</creatorcontrib><creatorcontrib>Fromont, Gaëlle</creatorcontrib><creatorcontrib>Wager, Michel</creatorcontrib><creatorcontrib>Levillain, Pierre</creatorcontrib><creatorcontrib>Cronier, Laurent</creatorcontrib><creatorcontrib>Monvoisin, Arnaud</creatorcontrib><creatorcontrib>Defamie, Norah</creatorcontrib><creatorcontrib>Mesnil, Marc</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Wiley Online Library Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crespin, Sophie</au><au>Fromont, Gaëlle</au><au>Wager, Michel</au><au>Levillain, Pierre</au><au>Cronier, Laurent</au><au>Monvoisin, Arnaud</au><au>Defamie, Norah</au><au>Mesnil, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2016-08</date><risdate>2016</risdate><volume>5</volume><issue>8</issue><spage>1742</spage><epage>1752</epage><pages>1742-1752</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. So far, diagnosis and prognosis of gliomas were based on histological and genetic criteria which need being completed by a panel of molecular markers. Highly distributed in brain, gap junction proteins, connexins, could be considered as markers of glioma progression as previous studies indicated that expression of a connexin type, connexin43 (Cx43), is inversely correlated to tumor grading. However, this assumption was weakened by the low number of glioma samples used. Taking advantage of tissue microarray technique, we pursued this analysis by studying in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). Our analysis confirmed the global diminution of Cx43 expression in glioblastomas that was observed in previous studies. However, this analysis brought new insights such as the following ones. First, the high number of samples permitted to show that more than 60% of glioblastomas still express Cx43. Second, no gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, a Cx43 nuclear staining was detected in areas where leukocytes are present. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.
Precise diagnosis of low and high grades of brain tumors permits determining therapeutical strategies. Highly distributed in brain, gap junction proteins, such as connexin 43, could be considered as markers of glioma progression. Taking advantage of tissue microarray technique, we analyzed in situ expression of Cx43 on 85 samples (37 grade IV, 18 grade III, 24 grade II, and 6 grades II to III). The high number of samples shows that 60% of glioblastomas still express Cx43. No gradual decrease in Cx43 expression was observed between grades II and III, but Cx43 appeared to be a marker distinguishing oligodendrocytic and astrocytic grade III tumors. Third, independently from tumor grade, the detection of a Cx43 nuclear staining seemed to be related to lymphocyte infiltrations. In conclusion, our study emphasizes the importance of in situ immunohistochemical approaches by giving more precise insights in the subcellular localization of Cx43. It also emphasizes the necessity to carry out such analysis on a wide range of samples to circumvent the high glioma heterogeneity.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>27306693</pmid><doi>10.1002/cam4.730</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7504-7538</orcidid><orcidid>https://orcid.org/0000-0002-5088-9325</orcidid><orcidid>https://orcid.org/0000-0003-4922-0365</orcidid><orcidid>https://orcid.org/0000-0002-9915-4872</orcidid><orcidid>https://orcid.org/0000-0002-7730-2264</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-7634 |
| ispartof | Cancer medicine (Malden, MA), 2016-08, Vol.5 (8), p.1742-1752 |
| issn | 2045-7634 2045-7634 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4971902 |
| source | PubMed (Medline); Wiley-Blackwell Open Access Collection; MEDLINE; Wiley Online Library Journals; Directory of Open Access Journals; EZB Electronic Journals Library |
| subjects | Adolescent Adult Aged Biomarkers, Tumor Biomarkers, Tumor - metabolism Blotting, Western Blotting, Western - methods Brain cancer Brain Neoplasms Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain tumors Cell Nucleus Cell Nucleus - metabolism Chemotaxis, Leukocyte Clinical Cancer Research Connexin 43 Connexin 43 - metabolism Connexins Cx43 Diagnosis Female gap junctions Glioblastoma Glioblastoma - metabolism Glioblastoma - pathology Glioma Glioma - metabolism Glioma - pathology gliomas Humans Leukocytes Life Sciences Localization Male Middle Aged Neoplasm Grading Neoplasm Proteins Neoplasm Proteins - metabolism Original Research Proteins Studies Tissue Array Analysis Tissue Array Analysis - methods Tumors Young Adult |
| title | Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T15%3A53%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20a%20gap%20junction%20protein,%20connexin43,%20in%20a%20large%20panel%20of%20human%20gliomas:%20new%20insights&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Crespin,%20Sophie&rft.date=2016-08&rft.volume=5&rft.issue=8&rft.spage=1742&rft.epage=1752&rft.pages=1742-1752&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.730&rft_dat=%3Cproquest_pubme%3E1809047773%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290232942&rft_id=info:pmid/27306693&rfr_iscdi=true |